Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro)
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Purpose: The present study sets out to evaluate the feasibility, safety, and effectiveness of conversion surgery following induction immunochemotherapy for patients with initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in a real-world scenario. Materials and Methods: In this multi-center, real-world study (NCT04822103), patients who had unresectable ESCC disease were enrolled across eight medical centers in China. All patients received programmed death receptor-1 (PD-1) inhibitor plus chemotherapy every 3 weeks for at least two cycles. Patients with significant relief of cancer-related clinical symptoms and radiological responsive disease were deemed surgical candidates. Feasibility and safety profile of immunochemotherapy plus conversion surgery, radiological and pathological tumor responses, as well as short-term survival outcomes were evaluated. Moreover, data of an independent ESCC cohort receiving induction chemotherapy (iC) were compared. Results: One hundred and fifty-five patients were enrolled in the final analysis. Esophagectomy was offered to 116 patients, yielding a conversion rate of 74.8%. R0 resection rate was 94%. Among the 155 patients, 107 (69.0%) patients experienced at least one treatment-related adverse event (TRAE) and 45 (29.0%) patients reported grade 3 and above TRAEs. Significant differences in responsive disease rate were observed between iC cohort and induction immunochemotherapy (iIC) cohort [objective response rate: iIC: 63.2% vs. iC: 47.7%, p = 0.004; pathological complete response: iIC: 22.4% vs. iC: 6.7%, p = 0.001). Higher anastomosis fistula rate was observed in the iC group (19.2%) compared with the iIC group (4%). Furthermore, Significantly higher event-free survival was observed in those who underwent conversion surgery. Conclusion: Our results supported that conversion surgery following immunochemotherapy is feasible and safe for patients with initially unresectable locally advanced ESCC. Both radiological and pathological response rates were significantly higher in the iIC cohort compared with those in the traditional iC cohort.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro)
- Date Crossref
- 13/07/2022
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Shantou University Department of Thoracic Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Shantou University Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Guangdong Academy of Medical Sciences pays non établi dans la noticeÉtablissement de santé
-
Guangdong Provincial People's Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
First Affiliated Hospital of Shantou University Medical College pays non établi dans la noticeÉtablissement de santé
-
Sun Yat-sen University Department of Thoracic Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Guangzhou Medical University Department of Thoracic Surgery pays non établi dans la noticeUniversité ou école supérieure
-
General Hospital of Guangzhou Military Command pays non établi dans la noticeÉtablissement de santé
-
Gaozhou People's Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Jinan University pays non établi dans la noticeUniversité ou école supérieure
-
Southern University of Science and Technology pays non établi dans la noticeUniversité ou école supérieure
-
Shantou Central Hospital Department of Surgical Oncology pays non établi dans la noticeÉtablissement de santé
Department of Thoracic Surgery — Shantou University, Shantou University Medical College et Guangdong Academy of Medical Sciences, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.